The UC San Diego (UCSD) Moores Cancer Center (MCC) has a rich history as a matrix, NCI-designated comprehensive cancer center, now with 239 members from 28 UCSD departments. Peer-reviewed MCC funding is $118.3 million (direct costs), of which $33.2 million is from the NCI. An additional $15.6 million from non-peer-reviewed sources results in total direct-cost funding of $133.9 million. We have published over 4000 cancer-focused papers in the funding period (20% inter- or intra-programmatic;10% in journals with an impact factor >15). MCC is surrounded by several other major life-science research institutes and 489 biotechnology companies in San Diego/La Jolla, the 2"''largest life-sciences cluster in the US. MCC is the only NCI-designated comprehensive cancer center in this region. MCC leverages this advantage to save lives by transforming cancer prevention, detection, and care (mission) and to make personalized cancer medicine a reality (vision). This is our first renewal application as a consortium center with partner San Diego State University (SDSU), thus formalizing long-standing, productive collaborations between MCC and SDSU. As designed, the MCC building 1) stimulates interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Basic Science, Clinical Science, and Population Science, 2) assembles the extensive NCI-supported Shared Resources in a common, accessible site, and 3) acts as an academia-industry hub for translational cancer researchers within the public and private sectors of San Diego. The vast majority of members are in the MCC building or on the UCSD campus;others are in nearby La Jolla institutes. This application reports on six Research Programs: Cancer Biology and Signaling, Cancer Genomes and Networks, Hematologic Malignancies, Solid Tumor Therapeutics, Cancer Prevention, and Reducing Cancer Disparities. We also propose seven Shared Resources: Biorepository and Tissue Technology, Biostatistics, Genomics and Bioinformatics, Microscopy, Flow Cytometry, Transgenic Mouse, Diet and Physical Activity. All Programs and Resources reflect the scientific strengths and goals of the MCC. MCC is poised to leverage its exceptional basic and population sciences and San Diego-wide collaborations (academic and private-sector) in developing innovative science-based cancer prevention and treatment. This application summarizes our investments, recruitments, collaborations, organizational changes, plans, and progress toward this goal. CCSG funding advances the UCSD Moores Cancer Center mission to save lives by transforming cancer prevention, detection, and care, and vision to make personalized cancer medicine a reality. The Cancer Center places the highest priority on basic discovery and its translation (via leveraging San Diego's unique academia-industry environment) into major clinical advances that reduce the burden of cancer.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
2P30CA023100-28
Application #
8666263
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
28
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Sen, Supriya; Langiewicz, Magda; Jumaa, Hassan et al. (2015) Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatology 61:171-83
Hoffmann, Hanne M; Tamrazian, Anika; Xie, Huimin et al. (2014) Heterozygous deletion of ventral anterior homeobox (vax1) causes subfertility in mice. Endocrinology 155:4043-53
Hartman, Lisa L R; Crawford, John R; Makale, Milan T et al. (2014) Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol 36:451-7
Williams, Richard T; Barnhill, Lisa M; Kuo, Huan-Hsien et al. (2014) Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth. PLoS One 9:e88219
Huang, Carlos P; Fofana, Mariama; Chan, Jefferson et al. (2014) Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics 6:654-61
Paolini, Paul; Pick, Daniel; Lapira, Jennifer et al. (2014) Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes. Pharmacogenomics 15:759-74
Goellner, Eva M; Smith, Catherine E; Campbell, Christopher S et al. (2014) PCNA and Msh2-Msh6 activate an Mlh1-Pms1 endonuclease pathway required for Exo1-independent mismatch repair. Mol Cell 55:291-304
Glidewell-Kenney, Christine A; Trang, Crystal; Shao, Paul P et al. (2014) Neurokinin B induces c-fos transcription via protein kinase C and activation of serum response factor and Elk-1 in immortalized GnRH neurons. Endocrinology 155:3909-19
Jiang, P; Mukthavaram, R; Chao, Y et al. (2014) In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer 111:1562-71
Jacques, Bonnie E; Montgomery 4th, William H; Uribe, Phillip M et al. (2014) The role of Wnt/*-catenin signaling in proliferation and regeneration of the developing basilar papilla and lateral line. Dev Neurobiol 74:438-56

Showing the most recent 10 out of 359 publications